拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎的疗效观察

• 作 者: 孙莉静 李保春 袁伟杰 于建平 许静 于光 郭志勇 付鹏 崔若兰
• 机 构: 上海第二军医大学附属长海医院肾内科,上海第二军医大学附属长海医院肾内科,上海第二军医大学附属长海医院肾内科,上海第二军医大学附属长海医院肾内科,上海第二军医大学附属长海医院肾内科,上海第二军医大学附属
• 出 处: 临床和实验医学杂志
• 发表日期: 2007年04期
• 关键词: 乙型肝炎病毒相关性肾炎 拉米夫定 治疗反应

目的观察拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎(HBV-GN)的疗效。方法32例符合条件的HBV-GN患者,随机分成治疗组和对照组,治疗组口服拉米夫定100mg/d,对照组服用血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体拮抗剂(ARB),治疗12个月,随访6个月。结果拉米夫定治疗组蛋白尿较对照组明显减少,肾功能稳定,仅1例患者因使用拉米夫定出现YVDD变异,无明显不良反应发生。结论拉米夫定治疗临床表现为肾炎综合征的乙型肝炎病毒相关性肾炎安全有效。

Objective To observe the efficacy of lamivudine in the treatment of hepatitis B virus nephritis (HBV-GN) with nephritic syndrome. Methods 32 eligible HBV-GN patients were randomly divided into treatment group and control group. The treatment group was given lamivudine 100 mg / d, while the control group received angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor antagonist (ARB) for 12 months and followed up for 6 months. Results Compared with the control group, the proteinuria of lamivudine treatment group was significantly reduced and the renal function was stable. Only one patient had YVDD mutation due to the use of lamivudine, and no obvious adverse reactions occurred. Conclusions Lamivudine is safe and effective in the treatment of hepatitis B virus-associated nephritis with nephritic syndrome.